Genmab has announced its planned acquisition of Merus in a deal worth approximately US$8 B, marking a strategic leap in its oncology portfolio. This acquisition grants Genmab full rights to Merus’ promising late-stage asset, petosemtamab, a novel bispecific antibody that targets epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), currently undergoing Phase III trials for head and neck cancer (HNSCC). This acquisition not only deepens Genmab’s expertise in antibody therapeutics but also positions it as a key player in the competitive oncology landscape.